371 related articles for article (PubMed ID: 23532667)
1. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
2. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
Geier A; Macias RI; Bettinger D; Weiss J; Bantel H; Jahn D; Al-Abdulla R; Marin JJ
Oncotarget; 2017 Feb; 8(9):15846-15857. PubMed ID: 28178663
[TBL] [Abstract][Full Text] [Related]
3. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
Martinez-Becerra P; Vaquero J; Romero MR; Lozano E; Anadon C; Macias RI; Serrano MA; Grañé-Boladeras N; Muñoz-Bellvis L; Alvarez L; Sangro B; Pastor-Anglada M; Marin JJ
Mol Pharm; 2012 Jun; 9(6):1693-704. PubMed ID: 22524153
[TBL] [Abstract][Full Text] [Related]
4. A rare primary liver tumor that responded to sorafenib.
Seino S; Tsuchiya A; Watanabe M
Gastroenterology; 2014 Dec; 147(6):1226-7. PubMed ID: 25450081
[No Abstract] [Full Text] [Related]
5. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
Grimm D; Lieb J; Weyer V; Vollmar J; Darstein F; Lautem A; Hoppe-Lotichius M; Koch S; Schad A; Schattenberg JM; Wörns MA; Weinmann A; Galle PR; Zimmermann T
BMC Cancer; 2016 Feb; 16():94. PubMed ID: 26872727
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma.
Lautem A; Heise M; Gräsel A; Hoppe-Lotichius M; Weiler N; Foltys D; Knapstein J; Schattenberg JM; Schad A; Zimmermann A; Otto G; Lang H; Galle PR; Schuchmann M; Zimmermann T
Int J Oncol; 2013 Apr; 42(4):1297-304. PubMed ID: 23440379
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.
Chen M; Neul C; Schaeffeler E; Frisch F; Winter S; Schwab M; Koepsell H; Hu S; Laufer S; Baker SD; Sparreboom A; Nies AT
Clin Pharmacol Ther; 2020 Jan; 107(1):227-237. PubMed ID: 31350763
[TBL] [Abstract][Full Text] [Related]
9. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.
Peveling-Oberhag J; Döring C; Hartmann S; Filmann N; Mertens A; Piiper A; Herrmann E; Hansmann ML; Zeuzem S; Trojan J; Welker MW
Clin Sci (Lond); 2015 Jan; 128(1):29-37. PubMed ID: 24959956
[TBL] [Abstract][Full Text] [Related]
11. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
[TBL] [Abstract][Full Text] [Related]
12. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
13. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Lee YS; Kim BH; Kim BC; Shin A; Kim JS; Hong SH; Hwang JA; Lee JA; Nam S; Lee SH; Bhak J; Park JW
Oncotarget; 2015 Jun; 6(18):16449-60. PubMed ID: 25965825
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
15. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
[TBL] [Abstract][Full Text] [Related]
16. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
17. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Godin C; Louandre C; Bodeau S; Diouf M; Saidak Z; Conte MA; Chauffert B; Barbare JC; Barget N; Trinchet JC; Ganne N; Galmiche A
Anticancer Res; 2015 Mar; 35(3):1803-8. PubMed ID: 25750346
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
20. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
